Quabodepistat was added as a strongly bactericidal cell wall inhibitor (36) in clinical trials for TB and trimetrexate as a potent but bacteriostatic Mab DHFR inhibitor (37), approved for the treatment of fungal infections. Here, DHFR is linked to fungal infectious disease.